Before coronary artery angiography (CAG), a fasting blood sample was assessed for lipid and Lp(a) levels. The synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) score was calculated according to the CAG results. Patients were divided into 3 groups based on CAD severity and SYNTAX scores. Results: Angiography revealed CAD in 270 patients. Lp(a) levels were higher in CAD compared to non-CAD patients (48.7 ± 23.8 mg/dl versus 18.9 ± 11.1 mg/dl [P <0.0001]). The levels of Lp(a) were lower in single than in double and triple vessels (39.3 ± 18.4 mg/dl versus 58.0 ± 23.0 mg/dl, and 69.2 ± 24.1 mg/dl, [P <0.05]). Lp(a) levels were significantly higher in severe CAD with SYNTAX score >30 (88.0±24.0 mg/dl). Lp(a) levels correlated significantly with SYNTAX scores (r = 0.70, P <0.0001). Conclusion: In this study, Lp(a) levels were positively associated with a patient's SYNTAX score in diseased vessels. Furthermore, an elevated Lp(a) level was a causal, independent risk factor of CAD. Lowering Lp(a) levels would reduce CAD in primary and secondary prevention settings. There is an urgent need to define more precisely which patients to treat and which to target for earlier interventions.
Advances in Knowledge -This study establishes the level of lipoprotein (a) [Lp(a)] which could be a predictive factor for angiographic-proven coronary artery
disease (CAD) in northern Indians. The presence of Lp(a) has emerged as a powerful genetic risk factor for coronary artery disease (CAD). [3] [4] [5] It is a complex molecule of low-density lipoprotein (LDL) to which a large, hydrophilic glycoprotein, apolipoprotein (a) [Apo(a)], is covalently linked via disulfide bonds. Based on its structure, Lp(a) has both atherogenic and prothrombotic properties. 6 In advanced atherosclerosis, Lp(a) is an independent risk factor not dependent on LDL. Lp(a) represents a coagulant risk of plaque thrombosis.
-High levels of triglycerides (TG) are a contributing factor in atherosclerosis. An increase in atherogenic particles, especially small dense low-density lipoprotein (LDL) cholesterol, may be a causative factor for the initiation and precipitation of coronary atherosclerosis. -Every region and race must have standardised cut-off levels for the early detection and prevention of CAD.
7 Apo(a) contains domains that are very similar to plasminogen, whose main function is to dissolve fibrin blood clots. Lp(a) accumulates in the vessel wall and inhibits the binding of plasminogen to the cell surface. This inhibition of Lp(a) also promotes the proliferation of smooth muscle cells. This unique feature suggests it causes the generation of clots and atherosclerosis.
Triglyceride-(TG) rich lipoproteins, which originate both in the intestines and liver, are considered an atherogenic factor. 8, 9 The aim of this study was to evaluate, in judging the severity of CAD, the association between the level of Lp(a) as a biomarker, and lipid status.
Methods
A cross-sectional study was conducted on 360 consecutive patients (300 male and 60 female) who underwent coronary angiography between June 2009 and October 2011 at the Sanjay Gandhi Postgraduate Institute of Medical Sciences and the King George's Medical University (KGMU) tertiary care hospitals in Lucknow, Uttar Pradesh, North India. The study was approved by KMGU's ethics committee. Subjects were informed of the objectives and procedure of the study and informed consent was taken with the consent form in both English and Hindi. The patients' demographic profiles, socioeconomic status, personal habits, and disease risk factor histories were recorded. Blood pressure (BP) was measured before the patients were sent to the catheterisation laboratory.
Patients with a history of chest pain, angina, acute myocardial infarction (AMI), non ST-segment elevation myocardial infarction (NSTEMI), unstable angina, and stable angina were included. All patients received long-term treatment with angiotensin-converting-enzyme (ACE) inhibitors, calcium (Ca) antagonists, or α-and β-adrenergic blocking agents. Almost all cases received statin treatment-most frequently atorvastatin. Patients with nephrotic syndrome, acute or chronic renal failure, thyroid disorders, acute infections, stroke, or diabetic ketoacidosis were excluded. Coronary angiography was performed using the Judkins technique, or a radial approach. interventional cardiologists, who were blinded to the serum Lp(a) analysis. In coronary angiography, the complexity of CAD was determined by an angiographic grading tool-the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) score. [11] [12] In principle, the SYNTAX score is the sum of the points assigned to each individual lesion identified in the coronary tree with >50% narrowing in the diameter of the vessels that measure greater than 1.5 mm. The percentage of stenosis was not a consideration. Only the presence of a stenosis from 50-99% in diameter, a narrowing of less than 50% in diameter, or a total occlusion were considered. The entire patient group was divided into two subgroups: subjects with CAD who had a SYNTAX score >0 and subjects without significant coronary artery stenosis with a SYNTAX score of 0.
Fasting blood samples were collected after a 10 to 12 hour fast and before cardiac catheterisation.
Samples were taken in sterile tubes, centrifuged at 3000 rpm for 10 minutes at 4°C, and then stored at -80°C until assayed. Fasting blood glucose (FBG), serum total cholesterol, high-density lipoprotein cholesterol (HDL-C), serum TG, and LDL-cholesterol (LDL-C) levels were estimated by standard methods. Lp(a) was measured by agglutination due to an antigen-antibody reaction between Lp(a) in a sample and anti-Lp(a) antibodies absorbed to latex particles. The assay range is approximately 3-90 mg/dl. Higher values of Lp(a) were rechecked by diluting the sample with normal saline. Results were then standardised.
The results are presented in mean ± standard deviation (SD) and percentage. The unpaired t-test was used to compare the two continous variables and one way analysis of variance (ANOVA) was used to compare more than two continous variables. The 95% confidence interval (CI) of means was also calculated. The Pearson correlation coefficient was calculated to find out the correlation between two variables. The P value <0.05 was considered significant. All the analysis was carried out by using the Statistical Package for the Social Sciences (SPSS), Version 15.0 (IBM, Chicago, IL, USA).
Results
The mean age of the patients was 54.0 ± 8.0 years, ranging from 30-65 years. A total of 270 patients (75%) of the 360 patients had angiographically- 1.4 ± 0.5 (124 ± 44) 0.001
1.9 ± 0.7 (75 ± 27) 0.02 proven CAD and 90 (25%) had normal coronary arteries (non-CAD group). The systolic and diastolic blood pressure was significantly higher in CAD patients (P <0.001) as compared to the non-CAD patients. The body mass index (BMI) was significantly higher in CAD patients (P <0.0001) as compared to non-CAD patients. There was a highly significant difference (P <0.0001) in the level of TG between CAD (2.0 ± 0.5 mmol/l) and non-CAD (1.4 ± 0.5 mmol/l) patients. A highly significant difference was observed in the level of very low density lipoproteins (VLDL) between CAD (0.9 ± 0.2 mmol/l) and non-CAD (0.6 ± 0.2 mmol/l) patients. However, the HDL was significantly lower (P <0.0001) in CAD patients (0.8 ± 0.2 mmol/l) as compared to non-CAD (1.0 ± 0.2 mmol/l) patients. Lp(a) levels were significantly higher in CAD (49 ± 24 mg/dl) than non-CAD patients (19 ± 11 mg/dl) [ Table 1 ].
Parameters were compared by vessel gradesLp(a) levels were significantly different among normal and different grades (P <0.0001). The HolmBonferroni pairwise comparison test showed that lipoprotein levels were significantly higher in all diseased vessels than those categorised as normal (P <0.0001) [ Table 2 ]. CAD subjects with diseased vessels had higher TG and VLDL levels, and lower HDL cholesterol concentrations in diseased vessels as compared to people with normal coronary status [ Table 3 ].
A subgroup analysis indicated that Lp(a) levels were significantly higher (P <0.0001) in patients with TG levels ≥150 mg/dl (47.6 ± 25.1 mg/dl) as compared to those with TG levels of <150 mg/ dl (25.2 ± 15.6 mg/dl). However, Lp(a) was higher (P <0.0001) in those with HDL-C levels of ≤40 mg/ dl (43.6 ± 24.9 mg/dl) than those with levels >40 (26.7 ± 20.0 mg/dl). Furthermore, Lp(a) levels were significantly lower (P <0.0001) among those whose TG levels were <150 mg/dl and HDL was >40 mg/ dl (15.6 ± 8.9 mg/dl) as compared to others (43.3 ± 24.6 mg/dl) [ Table 4 ].
CAD patients were classified according to their SYNTAX scores: <20, 20-30, and >30; Lp(a) levels in these subgroups were analysed and found significantly different [ Table 5 ]. According to the correlation coefficient, there was a positive association between Lp(a) levels and SYNTAX scores for the diseased vessel patient group (r = 0.70, P <0.0001) [ Figure 1 ].
Discussion
In this study, Lp(a) level >20 mg/dl was not only associated with the presence of coronary disease but also with the severity of the coronary atherosclerosis. This finding is consistent with previous reports. 13 A study carried out in southern India reported the cut-off level of Lp(a) as being 25 mg/dl for determination of a patient's risk of coronary heart disease (CHD).
14 Higher mean levels of Lp(a) were observed in our cases as compared to the control group in studies reported in other parts of India, where levels ranged from 12 to 41 mg/dl in CAD patients, and 8 to 24 mg/dl in healthy controls. [15] [16] [17] [18] Mean Lp(a) levels in patients in our study were also within the range of values reported in earlier Indian studies. 19 Upper limits of normal Lp(a) have not been defined in the Indian population. 15 In Caucasians, an Lp(a) of 30 mg/dl is considered the upper limit of normal. Erbagci et al. showed that the optimal cut-off values for Lp(a) levels were 22.6 and 9.8 mg/dl for men and women, respectively, in cases of CHD, with or without angiographically coronary status. High TG levels in our patients appeared to contribute to CAD risk. TG levels >130 mg/dl are strongly associated with the extent of a patient's coronary atherosclerosis; therefore, the present coronary angiography proven study is in agreement with the documented epidemiologic observations reported by Austin, which was that hypertriglyceridemia commonly occurrs in CAD patients [ Table 3 ]. [21] [22] [23] A delayed clearance of VLDL and chylomicron, and/or increased hepatic production of large VLDL results in the increased production of precursors of small dense LDL particles, a phenotype of which was reported to be associated with increased production of potentially atherogenic remnant-like particles. 24 Enrichment of the TG of this product through the action of cholesteryl ester transfer protein, together with hydrolysis of TG by hepatic lipase leads to an increased production of small dense LDL. Increased demonstrable lesions. 20 Our results showed Lp(a) as 21.4 mg/dl in minimal angiographically-proven single vessel disease even when cardiovascular risk factors and specific treatments (statins and/or aspirin) were taken into account; therefore, a level >20 mg/dl should be considered the cut-off value in the northern Indian population [ Table 2 ].
Contrary to the notion that these risk factors are highly prevalent in northern Indians, we found increased TG and very low HDL levels in diseased vessel patients as compared to those with normal levels of small dense LDL have been identified as a risk factor for an increased incidence of CAD in several epidemiological studies. 25 Furthermore, a subgroup analysis of TG and HDL-C cut-offs showed significant Lp(a) variation in our study. Significantly higher Lp(a) levels increased TG >150 mg/dl and it was also observed that Lp(a) levels markedly increased in subjects with low levels of HDL-C (P <.0001). Lp(a) levels depend on lipid profiles and suggest that treatment of dyslipidemia may also affect Lp(a) concentrations. Future studies are needed to clarify common mechanisms, enzymes, and receptors involved in Lp(a) and HDL/TG metabolism with a focus on how these mechanisms are modified in the setting of hypertriglyceridemia.
A marked raise in Lp(a) levels was found in patients with a SYNTAX score >30 (88 ± 24mg/ dl). Subjects with an intermediate to high SYNTAX score (20-30) observed higher Lp(a) levels (75 ± 16 mg/dl, P = 0.0001] as compared to subjects with low SYNTAX scores <20 (42 ± 18 mg/dl). These values shows that Lp(a) is directly related to SYNTAX score grading of atherosclerotic lesions. Our findings show that Lp(a) levels correlate with CAD severity [ Table 5 ] and with SYNTAX scores. Assuming that the SYNTAX score has the ability to describe anatomical and functional features of CAD, we suggest that Lp(a) levels can predict the extent of coronary artery impairment. The SYNTAX score predicts mortality and morbidity in patients irrespective of disease severity, at both short-and long-term follow-ups. The relationship between Lp(a) and the extent of CAD assessed by SYNTAX score had not been investigated in previous studies.
The mechanism implicated in the atherogenicity of Lp(a) includes proatherogenic Lp(a), via its apo(a) moiety, which is a proinflammatory molecule that directly interacts with the leukocyte β2-integrin Mac-1, thereby facilitating the recruitment of inflammatory cells. TGF-β1 activation is another mechanism via which Lp(a) contributes to the development of atherosclerotic vasculopathies. TGF-β1 is subject to proteolytic activation by plasmin and its active form leads to an inhibition of the proliferation and migration of smooth muscle cells, which play a central role in the formation and progression of atherosclerotic vascular diseases. If TGF-β1 fails to be activated, for example due to Lp(a) accumulation in the vascular wall, it is associated with an increased proliferation and migration of the smooth vascular muscle cells and the formation of atherosclerotic lesions. 26 In assessing appropriate cardiovascular preventive measures, clinical investigations using niacin alone or in combination with other lipidlowering agents such as statins have provided evidence for its dose-dependent cardiovascular benefit of up to 40%, and its amelioration of the global cardiovascular risk profile of patients. 27, 28 Bruckert et al. published a meta-analysis of 11 randomised controlled trials, involving 2,682 patients in the active group and 3,934 in the control group, which examined the effects of niacin alone or in combination with other lipidlowering drugs on cardiovascular events and atherosclerosis. 29 Recently, a report suggested that a 2-month treatment with a ginkgo biloba extract reduced Lp(a), with results attributed due to the anti-inflammatory effect of this natural extract. 30 Finally, there is reliable evidence to show that antiplatelet therapy with aspirin decreases platelet function, and may decrease plasma Lp(a) as well. The physiological basis of this pleiotropic effect of aspirin is still uncertain, although it may decrease the hepatic synthesis of apo(a) by inhibiting the transcriptional activity of the gene and suppressing messenger ribonucleic acid (RNA) expression. 31 Other studies investigated the effect of other compounds like carnitine and coenzyme Q10. [32] [33] [34] [35] [36] [37] A large number of apheresis techniques have been described based on plasma separation (lipid filtration, LDL-precipitation, and direct adsorption of lipoproteins). All methods have been primarily developed for treatment of high plasma LDL concentrations. However, because of the numerous structural similarities between LDL and Lp(a), the effect of these methods on both lipoproteins is very similar. Essentially, depending on the treated plasma or blood volume concentrations of Lp(a) and LDL, levels are lowered by 50-74 %, and >60 % at each therapy. Even other haemorheological parameters such as fibrinogen and viscosity are positively influenced. 38 This study confirms Lp(a) levels >20 mg/dl as a cut-off value to predict the severity of coronary atherosclerosis, suggesting that Lp(a) levels should be determined in patients with CAD, especially in normolipidemic individuals. Lp(a), considered an emerging risk factor by the National Cholesterol Education Program's (NCEP) Adult Treatment Panel (ATP) III, has been implicated in the development of the premature atherosclerotic disease seen in South Asians. 39 Among patients with excessive Lp(a), CAD risk increases 3-fold in the absence of other risk factors. The risk increases 8-fold with low HDL-C, 12-fold with high LDL-C, 16-fold with diabetes, and 25-fold with a TC/ HDL-C ratio. The higher the Lp(a) level the lower the age of first heart attack, and the most affected individuals develop myocardial infarction (MI) by the third to fifth decade of life. High levels of Lp(a) correlate with the prematurity, severity, extent, and progression of coronary atherosclerosis as well as the occurrence and recurrence of MI among Asian Indians. 40 Although all patients with hypertension and CAD require aggressive risk modification, the subgroup with high Lp(a) and TG levels may have multiple-vessel involvement and probably will need close clinical surveillance.
There are limitations to our study. The enrolled subjects might not be representative of the entire CAD population, as subjects recruited were referred to tertiary care for a coronary angioplasty restenosis trial (CART) and percutaneous transluminal coronary angioplasty (PTCA) and SYNTAX score grading considers over 50% coronary artery luminal reduction. The generally used estimation of luminal reduction is not exact and can be incorrect in spite of an investigator's experience.
Conclusion
In conclusion, this cross-sectional analysis suggests that Lp(a) levels differ significantly among Indians. The association between Lp(a) and cardiovascular outcomes may differ by race/ethnicity as well. Further studies should strive to disaggregate racial/ethnic groups and stratify by gender when examining Lp(a) among Asians. If replicated, our study suggests that the determination of Lp(a) levels may be particularly important in Asian Indians for the prevention of cardiovascular disease.
